Orchestra BioMed: Barclays raises PT to $12, maintains Overweight rating.

viernes, 9 de enero de 2026, 10:20 am ET1 min de lectura
OBIO--

Orchestra BioMed: Barclays raises PT to $12, maintains Overweight rating.

Orchestra BioMed: Barclays raises PT to $12, maintains Overweight rating.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios